Clearing Up Misperceptions About the Pain Standards

Published Online: Friday, November 1, 2013
Follow Pharmacy_Times:
In this podcast, Pat Adamski, director of the Joint Commission's Standards Interpretations Group, clears up common misperceptions about the organization's pain standards.

To listen to the podcast, click here.
Related Articles
Mylan Inc. announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex® Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.
Kit Check applies technology to automate hospital pharmacy kit restocking, which increases efficiency and accuracy while cutting costs.
When a would-be robber entered a pharmacy in Wyoming with what looked like a real gun, a pharmacist behind the counter reached for his firearm and injured the suspect by shooting him, according to the Wyoming Tribune Eagle.
A late-stage trial of extended-release hydrocodone bitartrate (Zohydro ER) pointed to a generally safe and well-tolerated response among patients with chronic pain for up to 1 year, according to Zogenix, Inc.
Latest Issues
$auto_registration$